FDA approves Alzheimer’s drug that slowed cognitive decline in clinical trial

FDA approves Alzheimer's drug that appears to modestly slow disease

An Alzheimer's drug that removes the substance amyloid from the brain has received a conditional approval from the FDA. A large study found the drug decreased the loss of thinking and memory by 27%.

Alzheimer's drug that modestly slows disease OK'd by FDA

Alzheimer's patients and their doctors will have to decide whether the potentially serious side effects are worth the drug's benefit.

New Alzheimer's drug slows disease, receives US approval

The United States Food and Drug Administration on Friday approved a new Alzheimer's drug for patients in the earliest stages of the mind-robbing...

US approves Alzheimer’s drug that can slow disease’s progress

US health officials have approved a drug that has been shown to slow the early stages of Alzheimer’s disease.

US approves Alzheimer’s drug that can slow disease’s progress

Rolling coverage of the international stories of interest to our readers

Eisai, Biogen get U.S. FDA approval for Alzheimer's drug, apply for full approval

By Julie Steenhuysen and Deena Beasley (Reuters) -The U.S. Food and Drug Administration on Friday approved the Alzheimer's drug lecanemab developed by Eisai Co Ltd and Biogen Inc for patients in the earliest stages of